

Infection risk: Comparing two IPP devices

Thousands of physicians and patients choose inflatable penile prostheses (IPPs) each year as a treatment for erectile dysfunction. Reducing the risk of infection is important, and IPP device selection can play a role, according to an analysis from Boston Scientific.

A 2025 analysis of real-world data from the Premier PINC AI™ Healthcare Database looked at patients who received either AMS 700™ (n = 3,636) or Coloplast Titan® (n = 2,830).^{*} Twelve known risk factors for IPP infection were used to characterize patients.¹

The analysis found that despite having more risk factors at baseline, AMS 700 patients had a **37.9%** lower infection rate than Titan patients (1.8% vs. 2.9%) at 180 days post-procedure.

26.9% of AMS 700 patients had a higher incidence of risk factors associated with infectious complications, versus only **19.2%** of Titan patients.

These findings suggest that post-IPP infection rates may be associated with device selection, along with patient characteristics.

^{*}Study funded by Boston Scientific. R. Sato, S. Rojanasart, and S. Telang report employment and equity or stocks with Boston Scientific Corporation. J. Loh-Doyle reports consulting or advisory relationships with Boston Scientific Corporation and Coloplast Titan in general. W. Brant and T-C Hsieh report consulting or advisory relationships with Boston Scientific Corporation in general. Authors have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors have no other conflicts of interest to declare.

POST-PROCEDURE INFECTION RATES




Figure 1a. Infection rate at 180 days and 3 years post-procedure for each device.

BASELINE COMORBIDITIES




Figure 1b. Percent of AMS 700 patients (n = 3,636) and Titan patients (n = 2,830) with these comorbidities.

The 12 known risk factors: age ≥ 75 years, smoking, concomitant circumcision, HIV, type 1 and type 2 diabetes (with and without comorbidities), previous pelvic radiation, urinary diversion, spinal cord injury, obesity, and Peyronie’s disease.

Treat your patients with the only antibiotic-impregnated penile implant on the market.

Learn more at [bostonscientific.com/ams700-inhibizone](https://www.bostonscientific.com/ams700-inhibizone)



Scan the QR code or click for [AMS 700 Indications, Safety, and Warnings.](#)

Boston Scientific

Boston Scientific Corporation
300 Boston Scientific Way
Marlborough, MA 01752
www.bostonscientific.com

1. [Nguyen V, Sato R, Rojanasart S, Telang S, Loh-Doyle J, Brant W, Hsieh T-C. Infection following inflatable penile prosthesis placement: A real-world comparison of device selection and patient characteristics. *Transl Androl Urol.* 2025;14:2635-2643.](#)

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

All trademarks are the property of their respective owners. All images are property of Boston Scientific.

©2026 Boston Scientific Corporation or its affiliates. All rights reserved. URO-2370209-AB JAN 2026